Allergenspezifische Immuntherapie (AIT) in Österreich

Allergen-specific immunotherapy (AIT) is the only causal treatment of the IgE mediated, type‑1 allergic diseases allergic rhinoconjunctivitis, bronchial asthma and anaphylaxis to hymenoptera stings. Usually, a patient will be treated via the subcutaneous (SCIT) or the sublingual (SLIT) route over 3 ...

Descripción completa

Detalles Bibliográficos
Autor principal: Wöhrl, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2020
Materias:
Allergologie
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607537/
http://dx.doi.org/10.1007/s12326-020-00406-6
_version_ 1783604665276956672
author Wöhrl, S.
author_facet Wöhrl, S.
author_sort Wöhrl, S.
collection PubMed
description Allergen-specific immunotherapy (AIT) is the only causal treatment of the IgE mediated, type‑1 allergic diseases allergic rhinoconjunctivitis, bronchial asthma and anaphylaxis to hymenoptera stings. Usually, a patient will be treated via the subcutaneous (SCIT) or the sublingual (SLIT) route over 3 years. Currently (end 2020), the German-language guidelines for AIT against inhalant allergens and venom immunotherapy (VIT) against bees and wasps are still being updated; thus, the recommendations in this article are based on the 2018 European Academy of Allergy and Clinical Immunology (EAACI) guidelines.
format Online
Article
Text
id pubmed-7607537
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-76075372020-11-03 Allergenspezifische Immuntherapie (AIT) in Österreich Wöhrl, S. hautnah Allergologie Allergen-specific immunotherapy (AIT) is the only causal treatment of the IgE mediated, type‑1 allergic diseases allergic rhinoconjunctivitis, bronchial asthma and anaphylaxis to hymenoptera stings. Usually, a patient will be treated via the subcutaneous (SCIT) or the sublingual (SLIT) route over 3 years. Currently (end 2020), the German-language guidelines for AIT against inhalant allergens and venom immunotherapy (VIT) against bees and wasps are still being updated; thus, the recommendations in this article are based on the 2018 European Academy of Allergy and Clinical Immunology (EAACI) guidelines. Springer Vienna 2020-11-03 2020 /pmc/articles/PMC7607537/ http://dx.doi.org/10.1007/s12326-020-00406-6 Text en © Springer-Verlag GmbH Austria, ein Teil von Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Allergologie
Wöhrl, S.
Allergenspezifische Immuntherapie (AIT) in Österreich
title Allergenspezifische Immuntherapie (AIT) in Österreich
title_full Allergenspezifische Immuntherapie (AIT) in Österreich
title_fullStr Allergenspezifische Immuntherapie (AIT) in Österreich
title_full_unstemmed Allergenspezifische Immuntherapie (AIT) in Österreich
title_short Allergenspezifische Immuntherapie (AIT) in Österreich
title_sort allergenspezifische immuntherapie (ait) in österreich
topic Allergologie
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607537/
http://dx.doi.org/10.1007/s12326-020-00406-6
work_keys_str_mv AT wohrls allergenspezifischeimmuntherapieaitinosterreich

Ejemplares similares